Date posted: 21 March 2024
BRISTOL, UK, 21st March 2024. Scarlet Therapeutics Ltd are thrilled to have been selected as one of Europe’s top 100 early-stage Deep Tech startups featured at Deep Tech Momentum 2024.
Deep Tech Momentum is an invite-only event where the best early-stage Deep Tech founders of Europe can meet the most relevant Deep Tech investors. The event will take place in 14-16th May in Berlin, Germany.
Our founders Jan Frayne, Alistair Irvine, Marjolein Meinders, Ash Toye will be attending along with some of the best European founders, VCs, corporate partners and founders. We would love to meet you there.
Details here: https://www.deeptech.build/
For press enquires please contact
Alistair Irvine
Tel: +44 75077 86615
Email: press@scarlet-tx.com
Website: www.scarlet-tx.com
LinkedIn: Scarlet Therapeutics Ltd | LinkedIn
About Scarlet Therapeutics
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, which have many advantageous qualities including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the RBC which are shielded from the immune system. Born out of more than a decade of research at the University of Bristol and the learning from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.